Search PubMed⌕ Search

PubMed · 7496008

A computer-based ordering system for supplies in national tuberculosis programs.

Abstract

SETTING: National tuberculosis programs in need of budgeting and planning for supplies. OBJECTIVE: To assist national managers to rationally and rapidly determine needs in supplies and their costs for the national tuberculosis program. METHODS: A spreadsheet has been developed to calculate needs in supplies for tuberculosis control based on the number of nationally notified cases. The spreadsheet has 3 interdependent basic components that need to be modified. The first component requires an update of exchange rates of currencies from countries which are major suppliers for program materials. The second component contains a list of commonly used treatment regimens in national programs and their cost. The number of reported tuberculosis cases for the last complete reporting half-year on then corresponding regimens needs to be provided. The third component lists supplies for diagnosis and treatment and the costs of these to the International Union Against Tuberculosis and Lung Disease (IUATLD). The information required here includes (after updating the country-specific list of suppliers and the cost of their material) the current stock in supplies and editing the resulting suggestion for orders according to needs and convenience of unit size. RESULTS: The spreadsheet suggests the ordering size of supplies for consumption and reserve. Based on input provided by the user, it will turn out estimates of the cost of the order for supplies in diagnosis and treatment. CONCLUSIONS: Computers are coming increasingly into use at the national level of many tuberculosis programs in low income countries. This spreadsheet, available from the IUATLD, is designed to provide national managers with the background on how to calculate needs for supplies and to provide them with a simple tool to assess these needs and their costs rapidly.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H L Rieder, D A Enarson. 1995. A computer-based ordering system for supplies in national tuberculosis programs.. https://doi.org/10.1016/0962-8479(95)90013-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Mechanism of thioamide drug action against tuberculosis and leprosy.

Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clinically effective in the treatment of Mycobacterium tuberculosis, M. leprae, and M. avium complex infections. Although generally considered second-line drugs for tuberculosis, their use has increased considerably as the number of multidrug resistant and extensively drug resistant tuberculosis cases continues to rise. Despite the widespread use of thioamide drugs to treat tuberculosis and leprosy, their precise mechanisms of action remain unknown. Using a cell-based activation method, we now have definitive evidence that both thioamides form covalent adducts with nicotinamide adenine dinucleotide (NAD) and that these adducts are tight-binding inhibitors of M. tuberculosis and M. leprae InhA. The crystal structures of the inhibited M. leprae and M. tuberculosis InhA complexes provide the molecular details of target-drug interactions. The purified ETH-NAD and PTH-NAD adducts both showed nanomolar Kis against M. tuberculosis and M. leprae InhA. Knowledge of the precise structures and mechanisms of action of these drugs provides insights into designing new drugs that can overcome drug resistance.

Antitubercular Agents↗

EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.

Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets. Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogues that do not require such processes. Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species. These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metabolism of ISO. Interestingly, biochemical analysis of [(14)C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets. This report is also the first description of the molecular mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries. Altogether, the results suggest that EthA is a common activator of thiocarbamide-containing drugs. The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems associated with clinical thiocarbamide use.

Antitubercular Agents↗